

RESEARCH ARTICLE

Molecular and epidemiological characterization of carbapenemase-producing Enterobacteriaceae in Norway, 2007 to 2014

Ørjan Samuelsen^{1,2*}, Søren Overballe-Petersen³, Jørgen Vildershøj Bjørnholt^{4‡}, Sylvain Brisse⁵, Michel Doumith⁶, Neil Woodford⁶, Katie L. Hopkins⁶, Bettina Aasnæs¹, Bjørg Haldorsen¹, Arnfinn Sundsfjord^{1,3}, on behalf of The Norwegian Study Group on CPE[†]



1 Norwegian National Advisory Unit on Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, Tromsø, Norway, **2** Microbial Pharmacology and Population Biology Research Group, Department of Pharmacy, UiT The Arctic University of Norway, Tromsø, Norway, **3** Research Group on Host-Microbe Interactions, Department of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway, **4** Department of Infectious Disease Epidemiology, Norwegian Institute of Public Health, Oslo, Norway, **5** Institut Pasteur, Biodiversity and Epidemiology of Bacterial Pathogens, Paris, France, **6** Antimicrobial Resistance and Healthcare Associated Infections (AMRHA) Reference Unit, National Infection Service, Public Health England, London, United Kingdom

OPEN ACCESS

Citation: Samuelsen Ø, Overballe-Petersen S, Bjørnholt JV, Brisse S, Doumith M, Woodford N, et al. (2017) Molecular and epidemiological characterization of carbapenemase-producing Enterobacteriaceae in Norway, 2007 to 2014. PLoS ONE 12(11): e0187832. <https://doi.org/10.1371/journal.pone.0187832>

Editor: Patrick Butaye, Ross University School of Veterinary Medicine, SAINT KITTS AND NEVIS

Received: June 14, 2017

Accepted: October 26, 2017

Published: November 15, 2017

Copyright: © 2017 Samuelsen et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Whole genome sequence data have been deposited at the National Center for Biotechnology Information (NCBI) under BioProject PRJNA295003. Original data regarding patient details have been aggregated to secure anonymity as approved by the Regional Ethical Committee and the Data Protection Officer at the University Hospital of North Norway. Complete data are available after consideration by the Regional Ethical Committee (rek-nord@asp.uit.no) / Data Protection Officer (personvernombudet@unn.no).

‡ Current address: Institute of Clinical Medicine, University of Oslo, Norway and Department of Clinical Microbiology, Oslo University Hospital, Oslo, Norway.

† Representatives of the Norwegian Study Group on CPE are listed in the acknowledgements

* orjan.samuelsen@unn.no

Abstract

The prevalence of carbapenemase-producing Enterobacteriaceae (CPE) is increasing worldwide. Here we present associated patient data and molecular, epidemiological and phenotypic characteristics of all CPE isolates in Norway from 2007 to 2014 confirmed at the Norwegian National Advisory Unit on Detection of Antimicrobial Resistance. All confirmed CPE isolates were characterized pheno- and genotypically, including by whole genome sequencing (WGS). Patient data were reviewed retrospectively. In total 59 CPE isolates were identified from 53 patients. Urine was the dominant clinical sample source (37%) and only 15% of the isolates were obtained from faecal screening. The majority of cases (62%) were directly associated with travel or hospitalization abroad, but both intra-hospital transmission and one inter-hospital outbreak were observed. The number of CPE cases/year was low (2–14 cases/year), but an increasing trend was observed. *Klebsiella* spp. ($n = 38$) and *E. coli* ($n = 14$) were the dominant species and bla_{KPC} ($n = 20$), bla_{NDM} ($n = 19$), bla_{OXA-48} -like ($n = 12$) and bla_{VIM} ($n = 7$) were the dominant carbapenemase gene families. The CPE isolates were genetically diverse except for *K. pneumoniae* where clonal group 258 associated with bla_{KPC} dominated. All isolates were multidrug-resistant and a significant proportion (21%) were resistant to colistin. Interestingly, all bla_{OXA-48} -like, and a large proportion of bla_{NDM} -positive *Klebsiella* spp. (89%) and *E. coli* (83%) isolates were susceptible *in vitro* to mecillinam. Thus, mecillinam could have a role in the treatment of uncomplicated urinary tract infections caused by OXA-48- or NDM-producing *E. coli* or *K. pneumoniae*. In

no) for researchers who meet the criteria for access to confidential data. All other data contained within the paper and Supporting Information.

Funding: The study was performed as part of our routine work and the authors received no specific funding for this study. There was no additional external funding received for this study.

Competing interests: PHE's AMRHAI Reference Unit has received financial support for conference attendance, lectures, research projects or contracted evaluations from numerous sources, including: Accelerate Diagnostics, Achaogen Inc., Allegra Therapeutics, Amplex, AstraZeneca UK Ltd, Basilea Pharmaceutica, Becton Dickinson Diagnostics, bioMérieux, Bio-Rad Laboratories, BSAC, Cepheid, Check-Points B.V., Cubist Pharmaceuticals, Department of Health, Enigma Diagnostics, Food Standards Agency, GlaxoSmithKline Services Ltd, Henry Stewart Talks, IHMA Ltd, Kalidex Pharmaceuticals, Melinta Therapeutics, Merck Sharpe & Dohme Corp., Meiji Seika Pharmo Co., Ltd, Mobidiag, Momentum Biosciences Ltd, Nordic Pharma Ltd, Norgine Pharmaceuticals, Rempex Pharmaceuticals Ltd, Roche, Rokitan Ltd, Smith & Nephew UK Ltd, Trius Therapeutics, VenatoRx Pharmaceuticals and Wockhardt Ltd. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

conclusion, the impact of CPE in Norway is still limited and mainly associated with travel abroad, reflected in the diversity of clones and carbapenemase genes.

Introduction

Carbapenemase-producing Enterobacteriaceae (CPE) have emerged as a global public health concern during the last two decades [1, 2]. CPE isolates are usually multidrug-resistant (MDR) or even extensively- or pandrug-resistant (XDR/PDR), resulting in limited antibiotic treatment options [1, 3, 4]. Due to the lack of effective therapy, CPE infections have been associated with high mortality rates [5, 6]. Currently, colistin and various combination regimens are generally used for treatment of CPE infections. However, the clinical evidence is mainly based on case reports and observational retrospective studies [1, 4]. Worryingly, high rates of colistin resistance among CPE have been observed in certain regions [7, 8]. Although colistin resistance is often mutation-based, plasmid-mediated colistin resistance has now also been described [9–14], and observed in CPE isolates [11, 15–17].

The main carbapenemases among Enterobacteriaceae include KPC (Ambler class A), the metallo- β -lactamases NDM, VIM and IMP (Ambler class B), and OXA-48-like enzymes (Ambler class D) [1]. Certain carbapenemases dominate in specific regions and countries, i.e. NDM in the Indian subcontinent, KPC in Italy, Portugal, Israel, Greece and the US, and OXA-48-like in many Mediterranean (e.g. Turkey and Malta) and North African countries as well as some other European countries (e.g. Belgium, France, Germany and Spain) [7, 18–20]. Specific clones or clonal groups (CG) are often associated with specific carbapenemases, while other carbapenemases show a more broad diversity with respect to host genetic backgrounds [2, 21]. The global spread of KPC has mainly been associated with *Klebsiella pneumoniae* sequence type (ST) 258 or CG 258 [2, 21, 22]. In contrast, NDM and OXA-48-like enzymes are broadly distributed in various genetic backgrounds of *K. pneumoniae* and *Escherichia coli* and for *bla*_{NDM} there is no clear link to a specific plasmid backbone [2, 21]. For *bla*_{OXA-48-like} there is molecular evidence supporting an association with a specific internationally epidemic IncL plasmid backbone [23–25].

The emergence of CPE in the Nordic countries has mainly been associated with single sporadic cases associated with import [26–36], and the prevalence is low compared with other European countries [7, 19]. However, there are indications of local dissemination unrelated to travel in Denmark [37, 38].

The aim of this study was to analyse the epidemiological, phenotypic and molecular characteristics of CPE isolated in Norway from 2007 to 2014 to understand the molecular epidemiology associated with the emergence of CPE in Norway.

Materials and methods

Bacterial strains and demographic data

The study collection consisted of 59 CPE isolates genetically-verified at the Norwegian National Advisory Unit on Detection of Antimicrobial Resistance from 2007–2014. The criteria for submitting isolates to the Unit included reduced susceptibility to carbapenems according to the Norwegian Working Group for Antibiotics (AFA, <https://unn.no/fag-og-forskning/arbeidsgruppen-for-antibiotikasporstmal-og-metoder-for-resistensbestemmelse-afa/>) Nordic Committee on Antimicrobial Susceptibility Testing (NordicAST) guidelines (www.nordicast.org). In 2012 mandatory reporting of confirmed CPE cases to the Norwegian Surveillance

System for Communicable Diseases (MSIS) was established. After confirmation at the Advisory Unit, MSIS and the primary lab are notified. The primary laboratory subsequently notifies the responsible clinician, who also reports data to MSIS. Clinical data were collected from the laboratory requisition. Multiple isolates from the same patient were included in the analysis if they were (i) of different species, (ii) the same species, but harboured a different carbapenemase gene or (iii) if the isolates were of the same species and harboured the same carbapenemase gene, but were identified >1 year apart.

Phenotypic analysis

Species identification was performed using MALDI-TOF MS (Bruker Daltonik GmbH, Bremen, Germany). MIC profiling was performed using gradient strips (Liofilchem, Roseto degli Abruzzi, Italy/bioMérieux, Marcy-l'Étoile, France) and broth microdilution for colistin using in-house designed premade Sensititre microtiter plates (TREK Diagnostic Systems/Thermo Fisher Scientific, East Grinstead, UK). Interpretation was according to EUCAST clinical breakpoints version 6.0 (www.eucast.org). Non-susceptibility included both the intermediate and resistant categories. The AmpC Confirm kit (ROSCO Diagnostica, Taastrup, Denmark), ESBL combination discs (Becton-Dickinson, Franklin Lakes, NJ, USA), KPC, MBL and OXA-48 Confirm kit (ROSCO Diagnostica) and the in-house version of Carba NP test were used for phenotypic typing of β -lactamases [39, 40].

Molecular analysis

The presence of carbapenemase genes was initially determined by various PCRs for *bla*_{KPC}, *bla*_{IMI}, *bla*_{VIM}, *bla*_{NDM}, *bla*_{IMP}, *bla*_{GIM}, *bla*_{SPM}, *bla*_{SIM} and *bla*_{OXA-48-like} [41–44]. WGS was performed on all isolates using the MiSeq platform (Illumina, San Diego, CA, USA) according to the manufacturer's instructions. Briefly, genomic DNA was purified using the GenElute bacterial genomic DNA kit (Sigma-Aldrich, St. Louis, MO, USA). DNA libraries were prepared using Nextera/Nextera XT kits (Illumina) followed by paired-end sequencing. Contigs were assembled using SPAdes [45] through the iMetAMOS extension [46] of the MetAMOS package [47]. The presence of resistance genes/mutations, carbapenemase genes and single nucleotide polymorphisms (SNP) variations were determined using a customised algorithm that uses Bowtie 2 to map reads against a locally curated reference database and assembled from publicly accessible databases. The database comprised sequences for all reported carbapenemase variants. Samtools was used to generate an mpileup file [48] which was then parsed based on read depth (> 10 reads per base) and base-call agreement (> 90%) to determine the base type at each nucleotide position relative to the closest reference sequence. Presence of reported carbapenemase variants were defined based on 100% identity across the whole length of the corresponding reference gene.

STs of *Klebsiella* spp., *E. coli* and *Enterobacter cloacae* complex were determined from WGS data using the *Klebsiella* MLST database (<http://bigsd.b.pasteur.fr/klebsiella/klebsiella.html>), EnteroBase (<http://enterobase.warwick.ac.uk/species/index/ecoli>) for *E. coli*, and the *E. cloacae* MLST database (<http://pubmlst.org/ecloacae>). Core genome MLST (cgMLST) was performed on *K. pneumoniae* isolates using 694 loci as previously described [22]. A phylogenetic tree was constructed based on the concatenated sequence alignments using RAxML [49] and FigTree (<http://tree.bio.ed.ac.uk/software/figtree/>).

Genbank accession numbers

WGS data have been deposited at the National Center for Biotechnology Information (NCBI) under BioProject PRJNA295003.

Ethical considerations

The study was reviewed and approved by the Regional Committee for Medical and Health Research Ethics North (reference no. 2016/2122/REK Nord and 2017/146/REK Nord) and the Data Protection Officer at the University Hospital of North Norway (reference no. 2017/1562). The need for patient consent was waived by the Regional Committee for Medical and Health Research Ethics North (reference no. 2017/146/REK nord)

Results

Bacterial isolates

In total 59 CPE were identified from 53 patients of which 44 were hospitalized patients. Samples from eight patients were taken at general practitioners or in other health care institutions (e.g. elderly care homes). For one patient no information was obtained. Of the 53 patients, four had multiple CPE isolates belonging to different species or different STs. One patient had four *bla*_{NDM-1}-positive strains of different species (*Proteus mirabilis*, *Providencia stuartii*, *Citrobacter* sp. and *K. pneumoniae*) isolated within a four-month period. Another had *bla*_{KPC-2}-positive *K. pneumoniae* and *Enterobacter cloacae* complex isolates in the same faecal screening sample. A third had *bla*_{NDM-1}-positive *E. coli* and *E. cloacae* complex isolates identified in two different specimens (wound secretion and urine, respectively) within a one-month period. The fourth patient yielded two *bla*_{NDM-1}-positive *K. pneumoniae* strains with unrelated STs from specimens taken 21 months apart.

Increasing number of CPE identified during the study period from a high proportion of clinical isolates

CPE isolates were identified in 14 of 22 clinical microbiology laboratories representing all health regions in Norway. The number of CPE cases per year, diversity of carbapenemase variants and species increased during the study period (Table 1), but with a trend towards dominance of NDM and OXA-48-like carbapenemase variants and increasing number of carbapenemase-producing *E. coli*. Fifty-six percent of the patients were male. The patient age ranged from 3–96

Table 1. Time-line and distribution of identified CPEs and carbapenemase variants. No. of isolates in parenthesis.

Year	No. of isolates	No. of cases ^a	<i>Klebsiella</i> sp.	<i>E. coli</i>	Other Enterobacteriaceae
2007	3	3	KPC-2 (1), VIM-1 (2)		
2008	6	6	KPC-2 (6)		
2009	2	2	KPC-2 (2)		
2010	8	7	KPC-2 (2), KPC-3 (1), VIM-27 (2), NDM-1 (1)	NDM-1 (1)	KPC-2 (1)
2011	4	4	KPC-2 (2), NDM-1+OXA-181 (1), OXA-48 (1)		
2012	16	14	KPC-2 (1), VIM-1 (1), NDM-1 (2), NDM-7 (1), OXA-245 (1)	VIM-29 (1), NDM-1 (1), NDM-5 (1), NDM-7 (1), OXA-48 (2)	NDM-1 (3), IMI-9 (1)
2013	8	7	KPC-3 (1), NDM-1 (2), OXA-48 (1), OXA-245 (1)	NDM-1 (1), OXA-48 (2)	
2014	12	10	KPC-2 (2), NDM-1 (2), OXA-48 (1), OXA-162 (1)	VIM-4 (1), NDM-1 (1), IMP-26 (1), OXA-181 (1)	KPC-2 (1), NDM-1 (1)
Total 2007–2014	59	53	KPC-2 (16), KPC-3 (2), VIM-1 (3), VIM-27 (2), NDM-1 (7), NDM-7 (1), NDM-1+OXA-181 (1), OXA-48 (3), OXA-162 (1), OXA-245 (2)	VIM-4 (1), VIM-29 (1), NDM-1 (4), NDM-4 (1), NDM-7 (1), IMP-26 (1), OXA-48 (4), OXA-181 (1)	KPC-2 (2), IMI-9 (1), NDM-1 (4)

^a Patients identified with multiple CPE defined as a single case.

<https://doi.org/10.1371/journal.pone.0187832.t001>

years (mean 63 and median 66 years). The majority of CPE were isolated from urine ($n = 22$, 37%), blood culture ($n = 9$, 15%) and faecal screening ($n = 9$, 15%).

Association with travel or hospitalization abroad

Thirty-three patients (62%) had a known history of travel and/or hospitalization abroad (Table 2). Sixteen patients (30%) reported no travel or hospitalization abroad and for four patients (8%), no information was obtained. With respect to the non-direct import cases, eight cases were associated with secondary spread from imported cases. This included six cases associated with a previously described, small but long-term outbreak of *bla*_{KPC-2}-positive *K. pneumoniae*/*E. cloacae* complex in 2007–2010 [50]. In addition, two other intra-hospital transmissions of *bla*_{KPC-2}-positive *K. pneumoniae* [28] and *bla*_{VIM-27}-positive *K. pneumoniae* were observed involving one additional patient in each case.

Bacterial species and carbapenemase diversity

Overall *Klebsiella* spp. (*K. pneumoniae*, $n = 36$; *Klebsiella variicola* $n = 1$; *Klebsiella quasipneumoniae* $n = 1$) were dominant, followed by *E. coli* ($n = 14$), *E. cloacae* complex ($n = 4$) and single isolates of *P. stuartii*, *P. mirabilis* and *Citrobacter* sp. (Table 1 and S1 Table). The most dominant carbapenemase gene family was *bla*_{KPC}, found in *K. pneumoniae* ($n = 18$) and *E. cloacae* complex ($n = 2$), followed by *bla*_{NDM} identified in *K. pneumoniae* ($n = 8$), *E. coli* ($n = 6$), *E. cloacae* complex ($n = 1$), *P. stuartii* ($n = 1$), *P. mirabilis* ($n = 1$) and *Citrobacter* sp. ($n = 1$). *bla*_{VIM} was identified in *K. pneumoniae* ($n = 4$), *E. coli* ($n = 2$) and *K. quasipneumoniae* ($n = 1$) while *bla*_{OXA-48-like} was identified in *K. pneumoniae* ($n = 5$), *E. coli* ($n = 5$) and *K. variicola* ($n = 1$). In addition, we identified one *K. pneumoniae* isolate harbouring both *bla*_{NDM} and *bla*_{OXA-48-like} and single isolates with *bla*_{IMI} (*E. cloacae* complex) and *bla*_{IMP} (*E. coli*). With respect to KPC, KPC-2 ($n = 18$) was the most predominant allele with the closest KPC-3 ($n = 2$) variant detected in only two isolates. The remaining carbapenemase genes encoded three different variants of NDM (NDM-1, $n = 16$; NDM-7, $n = 2$; and NDM-5, $n = 1$), four OXA-48-like (OXA-48, $n = 7$; OXA-181, $n = 2$; OXA-245, $n = 2$ and OXA-162, $n = 1$) and four VIM (VIM-1, $n = 3$; VIM-27, $n = 2$; VIM-4, $n = 1$; and VIM-29, $n = 1$). The single isolates with *bla*_{IMI} and *bla*_{IMP} encoded IMI-9 and IMP-26, respectively.

Bacterial population structure and linkage to specific carbapenemase alleles

MLST and cgMLST (Fig 1) showed that *K. pneumoniae* was dominated by KPC-producing clonal group (CG) 258, more specifically ST258 ($n = 15$) and its single locus variants (SLV) ST855 ($n = 1$) and ST340 ($n = 1$). The CG258 cluster comprised 21 isolates and included nearly all KPC-producers ($n = 17$) in addition to four ST11 isolates carrying *bla*_{NDM-1} ($n = 2$) or *bla*_{OXA-245} ($n = 2$) genes. Outside CG258, *bla*_{KPC} was only identified in one isolate belonging to ST461. Among the *K. pneumoniae* isolates cgMLST identified two other clusters represented by more than one isolate: one representing CG147 and including ST147 with *bla*_{VIM-27} ($n = 2$) or *bla*_{NDM-1} ($n = 1$) and ST273 with *bla*_{VIM-1} ($n = 1$), and one representing CG17 including ST17 with *bla*_{NDM-1} ($n = 2$) and ST336 with *bla*_{NDM-7} ($n = 1$). The remaining *K. pneumoniae* isolates represented genetically diverse single strains harbouring *bla*_{NDM-1} (ST37 and ST101), *bla*_{NDM-1} + *bla*_{OXA-181} (ST525), *bla*_{OXA-48} (ST187 and ST405), *bla*_{OXA-162} (ST14) and *bla*_{VIM-1} (ST2134). The *K. quasipneumoniae* isolate carrying *bla*_{VIM-1} belonged to ST1466 and the *K. variicola* with *bla*_{OXA-48} belonged to ST981.

Ten diverse genetic backgrounds were identified among the *E. coli* isolates ($n = 14$). None of the STs were SLVs or double locus variants (DLVs) of any other. Only ST38 ($n = 3$) and

Table 2. Distribution of isolates according to association with importation.

Country	No. of isolates	Species	Sequence type (ST)	Carbapenemase
Greece	7	<i>K. pneumoniae</i>	ST258	KPC-2
	1	<i>K. pneumoniae</i>	ST147	VIM-27
India	1	<i>K. pneumoniae</i>	ST11	NDM-1
	1	<i>K. pneumoniae</i>	ST17	NDM-1
	1 ^a	<i>K. pneumoniae</i>	ST147	NDM-1
	1	<i>E. coli</i>	ST101	NDM-7
	1	<i>E. coli</i>	ST131	NDM-1
	1	<i>E. coli</i>	ST410	NDM-1
Turkey	1	<i>K. pneumoniae</i>	ST273	VIM-1
	1	<i>K. variicola</i>	ST981	OXA-48
	1	<i>E. coli</i>	ST38	OXA-48
Serbia ^b	1	<i>K. pneumoniae</i>	ST17	NDM-1
	1	<i>P. stuartii</i>	-	NDM-1
	1	<i>P. mirabilis</i>	-	NDM-1
	1	<i>Citrobacter</i> sp.	-	NDM-1
Spain	1	<i>K. pneumoniae</i>	ST11	OXA-245
	1	<i>K. quasipneumoniae</i>	ST1466	VIM-1
	1	<i>E. cloacae</i> complex	ST635	IMI-9
Morocco	1	<i>K. pneumoniae</i>	ST405	OXA-48
	1	<i>K. pneumoniae</i>	ST11	OXA-245
Thailand	1	<i>E. coli</i>	ST405	OXA-48
	1	<i>E. coli</i>	ST6355	VIM-29
Brazil	1	<i>K. pneumoniae</i>	ST855	KPC-2
United Arab Emirates	1	<i>K. pneumoniae</i>	ST336	NDM-7
Syria/Jordan	1	<i>E. coli</i>	ST410	VIM-4
Jamaica	1	<i>E. cloacae</i> complex	ST456	KPC-2
Pakistan	1	<i>E. coli</i>	ST617	NDM-1
Romania	1	<i>K. pneumoniae</i>	ST525	NDM-1+OXA-181
Sri Lanka	1	<i>K. pneumoniae</i>	ST101	NDM-1
USA	1	<i>K. pneumoniae</i>	ST258	KPC-3
Unknown	1	<i>K. pneumoniae</i>	ST187	OXA-48
	2	<i>E. coli</i>	ST38	OXA-48
	1	<i>E. coli</i>	ST95	IMP-26
Norway (no reported overseas travel)	9 ^{c, d}	<i>K. pneumoniae</i>	ST258	KPC-2
	1	<i>K. pneumoniae</i>	ST14	OXA-162
	1 ^a	<i>K. pneumoniae</i>	ST37	NDM-1
	1 ^e	<i>K. pneumoniae</i>	ST147	VIM-27
	1 ^c	<i>K. pneumoniae</i>	ST461	KPC-2
	1	<i>K. pneumoniae</i>	ST2134	VIM-1
	1	<i>E. coli</i>	ST410	OXA-181
	1	<i>E. coli</i>	ST636	NDM-5
	1 ^f	<i>E. coli</i>	ST681	NDM-1
	1 ^f	<i>E. cloacae</i> complex	ST92	NDM-1
	1 ^c	<i>E. cloacae</i> complex	ST484	KPC-2

^a Two *bla*_{NDM-1}-positive *K. pneumoniae* isolates, one ST147 and one ST37, were isolated from the same patient. The isolates were identified 21 months apart where the first detection was associated with importation, but not for the second detection.

^b All four *bla*_{NDM-1}-positive isolates were isolated from the same patient.

^c Six *K. pneumoniae* ST258, one *K. pneumoniae* ST461 and one *E. cloacae* complex ST484, all *bla*_{KPC-2}-positive, were associated with a long-term outbreak [50]. The first case (*K. pneumoniae* ST258 with *bla*_{KPC-2}) of the outbreak were associated with import from Greece.

^d One *bla*_{KPC-2}-positive *K. pneumoniae* ST258 associated with intra-hospital transmission (first case associated with import from Greece)[28].

^e The *bla*_{VIM-27}-positive isolate were associated with a case of intra-hospital transmission (first case associated with import from Greece).

^f Both isolates identified from the same patient.

<https://doi.org/10.1371/journal.pone.0187832.t002>




Fig 1. Phylogenetic tree of *K. pneumoniae* isolates based on alignment of concatenated sequences of the 694 cgMLST scheme of *K. pneumoniae* [22]. The tree was constructed in RAxML [49] and visualized using FigTree (<http://tree.bio.ed.ac.uk/software/figtree/>). Clonal groups with >1 isolates are boxed. Sequence type (ST), carbapenemase gene and year of isolation is indicated for each isolate. Isolates associated with the long-term outbreak [50] and the two occurrences of intra-hospital transmission are labelled *, # and □, respectively.

<https://doi.org/10.1371/journal.pone.0187832.g001>

ST410 ($n = 3$) were represented by >1 isolate. All three ST38 isolates carried bla_{OXA-48} , while the three ST410 strains harboured each a different carbapenemase gene (bla_{NDM-1} , bla_{VIM-4} or $bla_{OXA-181}$). The remaining strains were genetically diverse and carried various carbapenemase genes/variants: bla_{NDM-1} (ST131, ST617 and ST681), bla_{NDM-5} (ST636), bla_{NDM-7} (ST101), bla_{OXA-48} (ST405), bla_{VIM-29} (ST6355) and bla_{IMP-26} (ST95).

The four carbapenemase-producing *E. cloacae* complex isolates were all of different STs: ST456 and ST484 both with *bla*_{KPC-2}, ST92 with *bla*_{NDM-1} and ST635 with *bla*_{IMI-9}. All STs were defined as singletons (no SLVs) by BURST analysis of the *E. cloacae* MLST database (<http://pubmlst.org/ecloacae/>, last accessed 24.06.2016).

Antimicrobial susceptibility profile and performance of phenotypic methods for detection of CPE

All isolates were multidrug-resistant (MDR) according to the definitions by Magiorakos *et al.* [51]. (Table 3 and S1 Table). One isolate, a *bla*_{NDM-1}-positive *P. stuartii* was non-susceptible to all relevant antimicrobial agents tested. Overall fosfomycin and colistin were the most active antimicrobial agents with 85% and 79% of the isolates being susceptible when excluding *P. mirabilis* and *P. stuartii* isolates which are intrinsically resistant to colistin [52] (Table 3).

Seven of the twelve colistin-resistant isolates were *K. pneumoniae* ST258 with *bla*_{KPC-2} (*n* = 6) or *bla*_{KPC-3} (*n* = 1). The other colistin-resistant isolates included *K. pneumoniae* ST525 with *bla*_{NDM-1} + *bla*_{OXA-181}, *K. pneumoniae* ST147 with *bla*_{NDM-1}, *K. pneumoniae* ST336 with *bla*_{NDM-7}, *E. cloacae* complex ST635 with *bla*_{IMI-9} and *E. cloacae* complex ST456 with *bla*_{KPC-2}.

High levels of non-susceptibility were observed to aminoglycosides (gentamicin, 51%; amikacin, 63%; and tobramycin, 83%), tigecycline (58%) and ciprofloxacin (83%).

With respect to the carbapenems, 41% were susceptible to meropenem, 39% to imipenem and 3% to ertapenem. All isolates had meropenem and ertapenem MIC values above the EUCAST screening breakpoint for carbapenemase detection (http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Resistance_mechanisms/EUCAST_detection_of

Table 3. Antimicrobial resistance profiles of CPE isolates according to species and carbapenemase variant.

Species	Carbapenemase	Percent non-susceptible (I+R) ^a																
		TZP	MEC	CXM	CTX	CAZ	ATM	MEM	ETP	IPM	GEN	AMK	TOB	CIP	TGC	SXT	CST	FOS
<i>Klebsiella</i> spp.	KPC (<i>n</i> = 18)	100	100	100	100	100	100	83	100	50	28	78	83	94	83	72	39	6
	VIM (<i>n</i> = 5)	100	100	100	100	100	40	60	100	80	0	40	100	100	40	80	0	0
	NDM (<i>n</i> = 9) ^b	100	11	100	100	100	100	89	100	67	78	89	100	89	56	78	33	11
	OXA-48-like (<i>n</i> = 6)	100	0	67	50	67	50	17	100	33	17	0	50	83	83	33	0	33
<i>E. coli</i>	VIM/IMP (<i>n</i> = 3)	67	67	100	100	100	100	33	67	67	100	100	100	33	33	100	0	33
	NDM (<i>n</i> = 6)	100	17	100	100	100	83	33	100	83	83	83	83	67	0	33	0	0
	OXA-48-like (<i>n</i> = 5)	100	0	100	100	100	100	20	100	20	80	0	80	60	20	80	0	0
<i>E. cloacae</i> complex	KPC (<i>n</i> = 2)	100	- ^c	100	100	100	100	100	100	100	50	50	50	100	50	50	50	100
	NDM (<i>n</i> = 1)	100	-	100	100	100	100	100	100	100	100	100	100	100	100	100	0	100
	IMI (<i>n</i> = 1)	0	-	0	0	0	100	0	100	100	0	0	0	0	100	0	100	0
<i>P. stuartii</i>	NDM (<i>n</i> = 1)	100	-	-	100	100	100	100	100	100	100	100	100	100	-	100	-	100
<i>P. mirabilis</i>	NDM (<i>n</i> = 1)	0	100	100	100	100	100	0	0	100	100	100	100	100	-	100	-	0
<i>Citrobacter</i> spp.	NDM (<i>n</i> = 1)	100	-	100	100	100	100	0	100	100	100	100	100	100	100	100	0	0
Total ^d		95	53	95	93	95	88	59	97	61	51	63	83	83	58	68	21	15

^a according to EUCAST clinical breakpoint table v. 6.0. TZP: piperacillin-tazobactam; MEC: mecillinam; CXM: cefuroxime; CTX: cefotaxime; CAZ: ceftazidime; AZT: aztreonam; MEM: meropenem; ETP: ertapenem; IPM: imipenem; GEN: gentamicin; AMK: amikacin; TOB: tobramycin; CIP: ciprofloxacin; TGC: tigecycline; SXT: trimethoprim-sulfamethoxazole; CST: colistin; FOS: fosfomycin.

^b includes one isolate co-harboring *bla*_{NDM-1} and *bla*_{OXA-181}.

^c "-" indicates lack of clinical breakpoint or intrinsic resistance according to EUCAST Expert Rules on Intrinsic Resistance and Exceptional Phenotypes v.3.1 (<http://www.eucast.org/>).

^d calculations excludes species/antibiotic combinations with intrinsic resistance.

[resistance_mechanisms_v1.0_20131211.pdf](#)) (S1 Table). For imipenem nine isolates had MIC values below the screening breakpoint. There was no clear correlation between carbapenemase variant and susceptibility to meropenem and imipenem with the exception that among the isolates harbouring *bla*_{OXA-48-like} (excluding the strain with both *bla*_{NDM-1} and *bla*_{OXA-181}) 9/11 and 8/11 were susceptible to meropenem and imipenem, respectively. As expected, a high level of resistance was observed against other β -lactams (Table 3 and S1 Table). Three isolates: one *K. pneumoniae* (*bla*_{OXA-48}), one *K. variicola* (*bla*_{OXA-48}) and the *bla*_{IMI-9}-positive *E. cloacae* complex isolate were susceptible to extended-spectrum cephalosporins (cefotaxime, ceftazidime and cefuroxime) and aztreonam. Interestingly, all OXA-48-like-positive *E. coli* and *Klebsiella* spp. as well as 83% and 89% of NDM-positive *E. coli* and *Klebsiella* spp. isolates, respectively were susceptible to mecillinam. Nine (15%) of the isolates tested negative for carbapenemase-production with the in-house Carba NP test (S1 Table), including six *bla*_{NDM-1}-positive isolates (*E. coli* *n* = 2, *P. stuartii*, *P. mirabilis*, *Citrobacter* sp. and *K. pneumoniae*), two *bla*_{OXA-48-like}-positive isolates (*E. coli* and *K. pneumoniae*) and one *E. cloacae* complex isolate (*bla*_{IMI-9}). The KPC, MBL and OXA-48 confirm kit correctly identified the presence of either an MBL or KPC in all relevant isolates except for one *bla*_{NDM-1}-positive *P. mirabilis* strain (S1 Table). The single *bla*_{IMI-9}-positive *E. cloacae* complex isolate also showed significant synergy with boronic acid only. With the exception of the isolate harbouring both *bla*_{NDM-1} and *bla*_{OXA-181}, where synergy was observed between meropenem and dipicolinic acid, no synergy was observed with the β -lactamase inhibitors for all *bla*_{OXA-48-like}-positive isolates. Moreover, with the exception of two isolates, all *bla*_{OXA-48-like}-positive isolates showed no zones of inhibition around the temocillin tablet, which may indicate the presence of OXA-48-like carbapenemases according to the manufacturer's guidelines. The meropenem-meropenem/EDTA gradient strip correctly identified all MBL-positive isolates, with the exception of the *K. pneumoniae* strain positive for both *bla*_{NDM-1} and *bla*_{OXA-181} where the test was inconclusive (S1 Table).

Association with other antibiotic resistance determinants

*Bla*_{CTX-M} and specifically *bla*_{CTX-M-15} were the most common ESBL variants identified and were mainly associated with *K. pneumoniae* and *E. coli* isolates with *bla*_{NDM} (10/15 isolates) or *bla*_{OXA-48-like} (8/11 isolates) and *E. coli* isolates with *bla*_{VIM} (2/2 isolates) (S1 Table). *Bla*_{CTX-M} were not identified in *bla*_{KPC}-positive *K. pneumoniae* isolates. One *E. coli* isolate with *bla*_{OXA-48} harboured both *bla*_{CTX-M-14} and *bla*_{CTX-M-15}. *bla*_{CTX-M-15} was also identified in one *bla*_{KPC-2}- and one *bla*_{NDM-1}-positive *E. cloacae* complex. *Bla*_{CMY} (*n* = 12) were the most common plasmid-mediated AmpC variants identified with *bla*_{CMY-6} particularly associated with *bla*_{NDM} (*n* = 9). The two *bla*_{OXA-48-like}-positive *Klebsiella* spp. isolates that were susceptible to extended-spectrum cephalosporins and aztreonam were negative for ESBL and plasmid-mediated AmpC genes.

In addition to various genes encoding aminoglycoside-modifying enzymes, the 16S rRNA methylase genes *rmtC* and *armA*, were identified in eight and five isolates, respectively (S1 Table). With the exception of the single isolate of *E. coli* with *bla*_{IMP-26}, *armA* and *rmtC* were only associated with isolates harbouring *bla*_{NDM-1}. In *Klebsiella* spp. insertional disruption of *mgrB* [53] associated with colistin resistance was identified in seven *K. pneumoniae* isolates (S1 Table). Insertional disruption of *mgrB* was also observed in two clinically colistin susceptible (MIC = 1 mg/L) *K. pneumoniae* isolates. One *K. pneumoniae* isolate with a disrupted *mgrB* also carried a nonsense mutation in *pmrB* leading to a truncated PmrB. Two colistin-resistant *K. pneumoniae* isolates had mutations in *pmrA* resulting in amino acid substitutions of G53C and D86E in one, and G53C in the other. In one colistin-resistant *Klebsiella* spp. isolate (MIC >8

mg/L) no previously described colistin resistance determinants were identified. The strain had mutations in *pmrA* (PmrA E57G) and *pmrB* (PmrB T246A) compared with the colistin-susceptible *K. pneumoniae* strain MGH 78578 [54], but neither mutation has been linked with colistin resistance and PmrB T246A is commonly found in *K. pneumoniae* [54]. No mutations were identified in *phoP*, *phoQ* or the *mgrB* promoter for this isolate. The plasmid-mediated colistin resistance genes *mcr-1* [9], *mcr-2* [10], *mcr-3* [12], *mcr-4* [13] and *mcr-5* [14] were not detected.

All *E. coli*, *K. pneumoniae* and *E. cloacae* complex isolates with high-level ciprofloxacin resistance (MIC \geq 32 mg/L) harboured mutations in both *gyrA* and *parC* (S1 Table). In addition, various plasmid-mediated quinolone resistance determinants were identified, including *aac(6′)-Ib-cr* ($n = 24$), *qnrB1* ($n = 8$), *qnrB4* ($n = 1$), *qnrB19* ($n = 2$), *qnrD* ($n = 1$) and *qnrS1* ($n = 8$).

Discussion

The main objective of this study was to gain a better understanding of the molecular epidemiology associated with the emergence of CPE in Norway. As observed in other Nordic countries [26, 27, 32–36] the emergence of CPE in Norway is also mainly associated with importation, highlighting the importance of targeted screening of patients hospitalized abroad and patients with a recent travel history to a country with a high prevalence of CPE. A relatively low number of cases (15%) were identified through faecal screening in contrast to Sweden (74,5%) and France (59.8%) [26, 55]. This difference is most likely due to dissimilarities in the use of targeted screening and that CPE screening in Norway was not fully implemented in the study period. This could also explain why a higher proportion of CPE cases in Sweden (81%) were associated with import [26]. Revised recommendations for infection prevention and control, including indications for screening for CPE, were introduced in Norway in August 2015 and in the first six months of 2016, 63% of CPE cases were identified through faecal screening. The occurrence of one long-term outbreak and two separate incidences of secondary transmission further highlights the importance of rapid implementation of infection prevention and control measures before confirmation of CPE if patients have risk factors (e.g. hospitalization abroad) or when an MDR isolate is identified.

The diversity of species and genetic backgrounds observed is probably due to the high degree of importation from a variety of countries (Table 2). Several studies have shown that the dissemination of resistance genes among clinical strains of Enterobacteriaceae is often associated with high-risk clones and the linkage between specific genetic backgrounds and resistance genes [2, 21, 56]. The cgMLST analysis of *K. pneumoniae* isolates showed that the observed epidemiology reflects the current global epidemiology (Fig 1), where *bla*_{KPC-2/-3} spread is primarily driven by strains associated with CG258 (and more specifically, ST258). In contrast, ST11 (a member of CG258, and a single locus variant of ST258) has been shown to be associated with a diversity of carbapenemase genes including *bla*_{KPC}, *bla*_{NDM}, *bla*_{VIM} and *bla*_{OXA-48-like} in different geographical regions [2, 57, 58]. Accordingly, the four ST11 strains in this study harboured either *bla*_{NDM-1} ($n = 2$) or *bla*_{OXA-245} ($n = 2$). Notably, cgMLST has shown that ST11 and ST340 represent a genetic sublineage within CG258 [22]. Isolates with *bla*_{NDM} and *bla*_{VIM} belonging to two other globally dispersed high-risk CGs like CG17 and CG147 [2] were also identified. The identification of *bla*_{VIM-1} and *bla*_{OXA-48} in *K. quasipneumoniae* and *K. variicola*, respectively shows that these *Klebsiella* species also contribute to the dissemination of carbapenemase genes and infections as both isolates were associated with infection. *K. variicola* have been shown to be frequently associated with bloodstream infections and associated with higher mortality than *K. pneumoniae* [59].

All three *E. coli* ST38 isolates harboured bla_{OXA-48} , which is consistent with previous observations showing a prevalent linkage of ST38 to bla_{OXA-48} in a large collection of clinical isolates from European and North-African countries [23]. In contrast, the three *E. coli* isolates belonging to ST410 were associated with different carbapenemase genes (bla_{NDM-1} , bla_{VIM-4} or $bla_{OXA-181}$) indicating the ability of this genetic background to maintain different plasmids and resistance genes. ST410 *E. coli* isolates have also previously been identified harbouring bla_{KPC-2} [60]. The global dissemination of bla_{NDM} has so far not been linked to specific high-risk clones or epidemic plasmids [21] and this is also reflected among the five bla_{NDM} -positive *E. coli* isolates, which belonged to five different genetic backgrounds. However, one strain belonged to the international high-risk clone ST131 [21] and another to ST101, which has previously been found to be associated with bla_{NDM} and other carbapenemases in several countries (e.g. Bangladesh [61], USA [62], Canada [63, 64] and Bulgaria [65]).

CPE frequently exhibit MDR or XDR phenotypes, limiting treatment options [1, 4]. This was also observed in our strain collection (Table 2 and S1 Table) due to the association with a wide variety of other acquired resistance genes, including 16S rRNA methylase genes conferring high-level broad-spectrum aminoglycoside resistance [66] and chromosomal mutations/insertions resulting in ciprofloxacin and colistin resistance (S1 Table). The mechanism(s) behind colistin resistance in one *K. pneumoniae* strain and the colistin-resistant *E. cloacae* isolates remains to be determined. Interestingly, a high prevalence of susceptibility to mecillinam among OXA-48- and NDM-producing *E. coli* and *K. pneumoniae* isolates was observed. Marrs *et al.* also showed high levels of *in vitro* susceptibility to mecillinam among NDM-producing *E. coli* and *K. pneumoniae* isolates from Pakistan [67], suggesting that mecillinam could have a role in the treatment of uncomplicated urinary tract infections caused by OXA-48- or NDM-producing *E. coli* or *K. pneumoniae* [68].

Rapid identification of CPE is essential for timely implementation of enhanced infection control measures to reduce transmission of CPE and prevent infections [3]. As observed in previous studies [69, 70] false-negative results (15%) for carbapenemase production were observed with the in-house version of the Carba NP test, particularly with NDM- and OXA-48-like-producing isolates. Identification of OXA-48-like-producers can be particularly challenging due to their relatively low level of activity against carbapenems and the lack of specific inhibitors [71]. The relatively high number of false-negative Carba NP results could also be due to the media used. In our study, colonies for the Carba NP test were harvested from MH agar and Literacka *et al.* have recently reported that MH agar from different companies were associated with false-negative results for MBL-producers [72]. High-level resistance to temocillin is a sensitive and specific indicator for the presence of OXA-48-like enzymes [73]. All bla_{OXA-48} -like-positive isolates in our collection showed high-level resistance (MIC > 128 mg/L) to temocillin, but several isolates harboring bla_{VIM} and bla_{NDM} also had temocillin MIC > 128 mg/L showing that testing for synergy with metal chelators (e.g. EDTA or dipicolinic acid) is necessary to discriminate between isolates with OXA-48 and MBLs.

Conclusions

The low prevalence of clinical CPE in Norway is consistent with the general low level of antimicrobial resistance compared with other countries. The relatively low level of antibiotic consumption and the use of narrow spectrum antibiotics [74] have probably contributed to this situation. The low prevalence is also reflected in the epidemiology of Norwegian CPE; mainly associated with importation, exhibiting a broad diversity of genetic backgrounds and carbapenemase variants that mirror the global epidemiology. Only a few cases of secondary spread also support this notion. In order to limit the infection pressure brought by increasing travel

and globalization, continued emphasis must be put on diagnostic capabilities, surveillance and infection control.

Supporting information

S1 Table. Strain collection and associated phenotypic and molecular data.
(XLSX)

Acknowledgments

Center for Bioinformatics at UiT The Arctic University of Norway is acknowledged for genome sequencing of part of the strain collection and initial bioinformatic analysis. We are grateful for assistance on the phylogenetic analysis of *Klebsiella* spp. by Jessin Janice and Ellen H. Josefsen for technical assistance. Tohru Miyoshi-Akiyama and colleagues are acknowledged for curating the *Enterobacter cloacae* MLST database and for providing novel STs.

This work was performed through a collaborative project with the diagnostic microbiology laboratories in Norway forming the Norwegian Study Group on CPE. We acknowledge the contributions of the representatives in the study group including: Trond E. Ranheim (Akershus University Hospital), Karianne Wiger Gammelsrud (Oslo University Hospital Rikshospitalet, Oslo University Hospital Aker and Oslo University Hospital Radiumhospitalet), Annette Onken (Vestre Viken Bærum Hospital), Kristina Papp (Vestre Viken Drammen Hospital), Liv Jorunn Sønsteby (Haugesund Hospital), Haima Mylvaganam (Haukeland University Hospital), Angela Kümmel (Levanger Hospital), Einar Nilsen (Molde Hospital), Hege Elisabeth Larsen (Nordland Hospital), Hans-Johnny Schjelderup Nilsen (St. Olavs University Hospital), Iren H. Löhr and Anita Brekken (Stavanger University Hospital), Anita Kanestrøm (Østfold Hospital), Guro Furset Jensen (Sørlandet Hospital), Nils Olav Hermansen (Oslo University Hospital Ullevål), Gunnar Skov Simonsen (University Hospital of North Norway), Dagfinn Skaare (Vestfold Hospital) and Reidar Hide (Ålesund Hospital).

Author Contributions

Conceptualization: Ørjan Samuelsen, Søren Overballe-Petersen, Arnfinn Sundsfjord.

Data curation: Ørjan Samuelsen, Søren Overballe-Petersen, Jørgen Vildershøj Bjørnholt, Sylvain Brisse, Michel Doumith, Katie L. Hopkins, Bettina Aasnæs, Bjørg Haldorsen.

Formal analysis: Ørjan Samuelsen, Michel Doumith.

Funding acquisition: Ørjan Samuelsen, Sylvain Brisse, Neil Woodford, Arnfinn Sundsfjord.

Investigation: Ørjan Samuelsen, Søren Overballe-Petersen, Jørgen Vildershøj Bjørnholt, Michel Doumith, Katie L. Hopkins, Bettina Aasnæs, Bjørg Haldorsen.

Methodology: Sylvain Brisse, Michel Doumith.

Project administration: Ørjan Samuelsen, Arnfinn Sundsfjord.

Resources: Ørjan Samuelsen, Jørgen Vildershøj Bjørnholt, Sylvain Brisse, Michel Doumith, Neil Woodford, Katie L. Hopkins, Arnfinn Sundsfjord.

Software: Sylvain Brisse, Michel Doumith.

Supervision: Ørjan Samuelsen, Sylvain Brisse, Neil Woodford, Arnfinn Sundsfjord.

Validation: Ørjan Samuelsen, Søren Overballe-Petersen, Jørgen Vildershøj Bjørnholt, Sylvain Brisse, Michel Doumith, Neil Woodford, Katie L. Hopkins, Bettina Aasnæs, Bjørg Haldorsen, Arnfinn Sundsfjord.

Visualization: Ørjan Samuelsen.

Writing – original draft: Ørjan Samuelsen.

Writing – review & editing: Ørjan Samuelsen, Søren Overballe-Petersen, Jørgen Vildershøj Bjørnholt, Sylvain Brisse, Michel Doumith, Neil Woodford, Katie L. Hopkins, Bettina Aasnæs, Bjørg Haldorsen, Arnfinn Sundsfjord.

References

1. Tangden T, Giske CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. *J Int Med.* 2015; 277(5):501–12.
2. Pitout JD, Nordmann P, Poirel L. Carbapenemase-producing *Klebsiella pneumoniae*: a key pathogen set for global nosocomial dominance. *Antimicrob Agents Chemother.* 2015; 59(10):5873–84. <https://doi.org/10.1128/AAC.01019-15> PMID: 26169401
3. Temkin E, Adler A, Lerner A, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management. *Ann N Y Acad Sci.* 2014; 1323:22–42. <https://doi.org/10.1111/nyas.12537> PMID: 25195939
4. Perez F, El Chakhtoura NG, Papp-Wallace KM, Wilson BM, Bonomo RA. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy? *Expert Opin Pharmacother.* 2016; 17(6):761–81. <https://doi.org/10.1517/14656566.2016.1145658> PMID: 26799840
5. Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, et al. Infections caused by KPC-producing *Klebsiella pneumoniae*: differences in therapy and mortality in a multicentre study. *J Antimicrob Chemother.* 2015; 70(7):2133–43. <https://doi.org/10.1093/jac/dkv086> PMID: 25900159
6. Doi Y, Paterson DL. Carbapenemase-producing Enterobacteriaceae. *Semin Resp Crit Care Med.* 2015; 36(1):74–84.
7. Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasevic AT, et al. Occurrence of carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. *Lancet Infect Dis.* 2017; 17(2):153–63. [https://doi.org/10.1016/S1473-3099\(16\)30257-2](https://doi.org/10.1016/S1473-3099(16)30257-2) PMID: 27866944
8. Monaco M, Giani T, Raffone M, Arena F, Garcia-Fernandez A, Pollini S, et al. Colistin resistance superimposed to endemic carbapenem-resistant *Klebsiella pneumoniae*: a rapidly evolving problem in Italy, November 2013 to April 2014. *Euro Surveill* 2014; 19(42) pii: 20939.
9. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis.* 2016; 16(2):161–8. [https://doi.org/10.1016/S1473-3099\(15\)00424-7](https://doi.org/10.1016/S1473-3099(15)00424-7) PMID: 26603172
10. Xavier BB, Lammens C, Ruhel R, Kumar-Singh S, Butaye P, Goossens H, et al. Identification of a novel plasmid-mediated colistin-resistance gene, *mcr-2*, in *Escherichia coli*, Belgium, June 2016. 2016; 21(27) <https://doi.org/10.2807/1560-7917.ES.2016.21.27.30280> PMID: 27416987
11. Di Pilato V, Arena F, Tascini C, Cannatelli A, Henrici De Angelis L, Fortunato S, et al. *mcr-1.2*, a new *mcr* variant carried on a transferable plasmid from a colistin-resistant KPC carbapenemase-producing *Klebsiella pneumoniae* strain of sequence type 512. *Antimicrob Agents Chemother.* 2016; 60(9):5612–5. <https://doi.org/10.1128/AAC.01075-16> PMID: 27401575
12. Yin W, Li H, Shen Y, Liu Z, Wang S, Shen Z, et al. Novel plasmid-mediated colistin resistance gene *mcr-3* in *Escherichia coli*. *mBio.* 2017; 8(3) pii: e00543-17.
13. Carattoli A, Villa L, Feudi C, Curcio L, Orsini S, Luppi A, et al. Novel plasmid-mediated colistin resistance *mcr-4* gene in *Salmonella* and *Escherichia coli*, Italy 2013, Spain and Belgium, 2015 to 2016. *Euro Surveill.* 2017; 22(31) pii: 30589.
14. Borowiak M, Fischer J, Hammerl JA, Hendriksen RS, Szabo I, Malorny B. Identification of a novel transposon-associated phosphoethanolamine transferase gene, *mcr-5*, conferring colistin resistance in d-tartrate fermenting *Salmonella enterica* subsp. *enterica* serovar Paratyphi B. *J Antimicrob Chemother.* 2017; Sep 18. doi: 10.1093/jac/dkx327. [Epub ahead of print]. PMID: 28962028

15. Falgenhauer L, Waezsada SE, Yao Y, Imirzalioglu C, Kasbohrer A, Roesler U, et al. Colistin resistance gene *mcr-1* in extended-spectrum- β -lactamase-producing and carbapenemase-producing Gram-negative bacteria in Germany. *Lancet Infect Dis*. 2016; 16(3):282–3. [https://doi.org/10.1016/S1473-3099\(16\)00009-8](https://doi.org/10.1016/S1473-3099(16)00009-8) PMID: 26774242
16. Mulvey MR, Mataseje LF, Robertson J, Nash JH, Boerlin P, Toye B, et al. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis*. 2016; 16(3):289–90. [https://doi.org/10.1016/S1473-3099\(16\)00067-0](https://doi.org/10.1016/S1473-3099(16)00067-0) PMID: 26973304
17. Li A, Yang Y, Miao M, Chavda KD, Mediavilla JR, Xie X, et al. Complete sequences of *mcr-1*-harboring plasmids from extended-spectrum- β -lactamase- and carbapenemase-producing Enterobacteriaceae. *Antimicrob Agents and Chemother*. 2016; 60(7):4351–4.
18. Nordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. *Clin Microbiol Infect*. 2014; 20(9):821–30. <https://doi.org/10.1111/1469-0691.12719> PMID: 24930781
19. Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL, European Survey of Carbapenemase-Producing Enterobacteriaceae working group. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. *Euro Surveill*. 2015; 20(45) <https://doi.org/10.2807/1560-7917.ES.2015.20.45.30062> PMID: 26675038
20. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. *J Infect Dis*. 2017; 215(suppl_1):S28–S36. <https://doi.org/10.1093/infdis/jiw282> PMID: 28375512
21. Mathers AJ, Peirano G, Pitout JD. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. *Clin Microbiol Rev*. 2015; 28(3):565–91. <https://doi.org/10.1128/CMR.00116-14> PMID: 25926236
22. Bialek-Davenet S, Criscuolo A, Ailloud F, Passet V, Jones L, Delannoy-Vieillard AS, et al. Genomic definition of hypervirulent and multidrug-resistant *Klebsiella pneumoniae* clonal groups. *Emerg Infect Dis*. 2014; 20(11):1812–20. <https://doi.org/10.3201/eid2011.140206> PMID: 25341126
23. Potron A, Poirel L, Rondinaud E, Nordmann P. Intercontinental spread of OXA-48 β -lactamase-producing Enterobacteriaceae over a 11-year period, 2001 to 2011. *Euro Surveill*. 2013; 18(31) pii: 20549.
24. Poirel L, Bonnin RA, Nordmann P. Genetic features of the widespread plasmid coding for the carbapenemase OXA-48. *Antimicrob Agents Chemother*. 2012; 56(1):559–62. <https://doi.org/10.1128/AAC.05289-11> PMID: 22083465
25. Carattoli A, Seiffert SN, Schwendener S, Perreten V, Endimiani A. Differentiation of IncL and IncM plasmids associated with the spread of clinically relevant antimicrobial resistance. *PLoS ONE*. 2015; 10(5): e0123063. <https://doi.org/10.1371/journal.pone.0123063> PMID: 25933288
26. Lofmark S, Sjostrom K, Makitalo B, Edquist P, Tegmark Wisell K, Giske CG. Carbapenemase-producing Enterobacteriaceae in Sweden 2007–2013: Experiences from seven years of systematic surveillance and mandatory reporting. *Drug Resist Updates*. 2015; 20:29–38.
27. Osterblad M, Kirveskari J, Hakanen AJ, Tissari P, Vaara M, Jalava J. Carbapenemase-producing Enterobacteriaceae in Finland: the first years (2008–11). *J Antimicrob Chemother*. 2012; 67(12):2860–4. <https://doi.org/10.1093/jac/dks299> PMID: 22855858
28. Samuelsen Ø, Naseer U, Tofteland S, Skutlaberg DH, Onken A, Hjetland R, et al. Emergence of clonally related *Klebsiella pneumoniae* isolates of sequence type 258 producing plasmid-mediated KPC carbapenemase in Norway and Sweden. *J Antimicrob Chemother*. 2009; 63(4):654–8. <https://doi.org/10.1093/jac/dkp018> PMID: 19218573
29. Samuelsen Ø, Naseer U, Karah N, Lindemann PC, Kanestrom A, Leegaard TM, et al. Identification of Enterobacteriaceae isolates with OXA-48 and coproduction of OXA-181 and NDM-1 in Norway. *J Antimicrob Chemother*. 2013; 68(7):1682–5. <https://doi.org/10.1093/jac/dkt058> PMID: 23463214
30. Samuelsen Ø, Thilesen CM, Heggelund L, Vada AN, Kummel A, Sundsfjord A. Identification of NDM-1-producing Enterobacteriaceae in Norway. *J Antimicrob Chemother*. 2011; 66(3):670–2. <https://doi.org/10.1093/jac/dkq483> PMID: 21172785
31. Samuelsen Ø, Toleman MA, Hasseltvedt V, Fursted K, Leegaard TM, Walsh TR, et al. Molecular characterization of VIM-producing *Klebsiella pneumoniae* from Scandinavia reveals genetic relatedness with international clonal complexes encoding transferable multidrug resistance. *Clin Microbiol Infect*. 2011; 17(12):1811–6. <https://doi.org/10.1111/j.1469-0691.2011.03532.x> PMID: 21595797
32. Hammerum AM, Littauer P, Hansen F. Detection of *Klebsiella pneumoniae* co-producing NDM-7 and OXA-181, *Escherichia coli* producing NDM-5 and *Acinetobacter baumannii* producing OXA-23 in a single patient. *Int J Antimicrob Agents*. 2015; 46(5):597–8. <https://doi.org/10.1016/j.ijantimicag.2015.07.008> PMID: 26307465

33. Jakobsen L, Hammerum AM, Hansen F, Fuglsang-Damgaard D. An ST405 NDM-4-producing *Escherichia coli* isolated from a Danish patient previously hospitalized in Vietnam. *J Antimicrob Chemother.* 2014; 69(2):559–60. <https://doi.org/10.1093/jac/dkt356> PMID: 24013194
34. Hammerum AM, Larsen AR, Hansen F, Justesen US, Friis-Møller A, Lemming LE, et al. Patients transferred from Libya to Denmark carried OXA-48-producing *Klebsiella pneumoniae*, NDM-1-producing *Acinetobacter baumannii* and methicillin-resistant *Staphylococcus aureus*. *Int J Antimicrob Agents.* 2012; 40(2):191–2.
35. Nielsen JB, Hansen F, Littauer P, Schønning K, Hammerum AM. An NDM-1-producing *Escherichia coli* obtained in Denmark has a genetic profile similar to an NDM-1-producing *E. coli* isolate from the UK. *J Antimicrob Chemother.* 2012; 67(8):2049–51. <https://doi.org/10.1093/jac/dks149> PMID: 22532468
36. Hammerum AM, Toleman MA, Hansen F, Kristensen B, Lester CH, Walsh TR, et al. Global spread of New Delhi metallo- β -lactamase 1. *Lancet Infect Dis.* 2010; 10(12):829–30. [https://doi.org/10.1016/S1473-3099\(10\)70276-0](https://doi.org/10.1016/S1473-3099(10)70276-0) PMID: 21109169
37. Wang M, Ellermann-Eriksen S, Hansen DS, Kjerulf A, Fuglsang-Damgaard D, Holm A, et al. Epidemic increase in the incidence of carbapenemase-producing Enterobacteriaceae in Denmark. *Ugeskr Laeger.* 2016; 178(45): pii: V06160422.
38. Hammerum AM, Hansen F, Nielsen HL, Jakobsen L, Stegger M, Andersen PS, et al. Use of WGS data for investigation of a long-term NDM-1-producing *Citrobacter freundii* outbreak and secondary *in vivo* spread of *bla*_{NDM-1} to *Escherichia coli*, *Klebsiella pneumoniae* and *Klebsiella oxytoca*. *J Antimicrob Chemother.* 2016; 71(11):3117–24. <https://doi.org/10.1093/jac/dkw289> PMID: 27494919
39. Nordmann P, Poirel L, Dortet L. Rapid detection of carbapenemase-producing Enterobacteriaceae. *Emerg Infect Dis.* 2012; 18(9):1503–7. <https://doi.org/10.3201/eid1809.120355> PMID: 22932472
40. Dortet L, Brechard L, Poirel L, Nordmann P. Impact of the isolation medium for detection of carbapenemase-producing Enterobacteriaceae using an updated version of the Carba NP test. *J Med Microbiol.* 2014; 63(Pt 5):772–6. <https://doi.org/10.1099/jmm.0.071340-0> PMID: 24591705
41. Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P. Genetic structures at the origin of acquisition of the β -lactamase *bla*_{KPC} gene. *Antimicrob Agents Chemother.* 2008; 52(4):1257–63. <https://doi.org/10.1128/AAC.01451-07> PMID: 18227185
42. Mendes RE, Kiyota KA, Monteiro J, Castanheira M, Andrade SS, Gales AC, et al. Rapid detection and identification of metallo- β -lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. *J Clin Microbiol.* 2007; 45(2):544–7. <https://doi.org/10.1128/JCM.01728-06> PMID: 17093019
43. Swayne RL, Ludlam HA, Shet VG, Woodford N, Curran MD. Real-time TaqMan PCR for rapid detection of genes encoding five types of non-metallo- (class A and D) carbapenemases in Enterobacteriaceae. *Int J Antimicrob Agents.* 2011; 38(1):35–8. <https://doi.org/10.1016/j.ijantimicag.2011.03.010> PMID: 21549572
44. Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. *Diag Microbiol Infect Dis.* 2011; 70(1):119–23.
45. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol.* 2012; 19(5):455–77. <https://doi.org/10.1089/cmb.2012.0021> PMID: 22506599
46. Koren S, Treangen TJ, Hill CM, Pop M, Phillippy AM. Automated ensemble assembly and validation of microbial genomes. *BMC Bioinformatics.* 2014; 15:126. <https://doi.org/10.1186/1471-2105-15-126> PMID: 24884846
47. Treangen TJ, Ondov BD, Koren S, Phillippy AM. The Harvest suite for rapid core-genome alignment and visualization of thousands of intraspecific microbial genomes. *Genome Biol.* 2014; 15(11):524. <https://doi.org/10.1186/s13059-014-0524-x> PMID: 25410596
48. Doumith M, Day M, Ciesielczuk H, Hope R, Underwood A, Reynolds R, et al. Rapid identification of major *Escherichia coli* sequence types causing urinary tract and bloodstream infections. *J Clin Microbiol.* 2015; 53(1):160–6. <https://doi.org/10.1128/JCM.02562-14> PMID: 25355761
49. Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. *Bioinformatics.* 2014; 30(9):1312–3. <https://doi.org/10.1093/bioinformatics/btu033> PMID: 24451623
50. Tofteland S, Naseer U, Lislevand JH, Sundsfjord A, Samuelsen Ø. A long-term low-frequency hospital outbreak of KPC-producing *Klebsiella pneumoniae* involving Intergenous plasmid diffusion and a persisting environmental reservoir. *PLoS ONE.* 2013; 8(3):e59015. <https://doi.org/10.1371/journal.pone.0059015> PMID: 23536849
51. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect.* 2012; 18(3):268–81. <https://doi.org/10.1111/j.1469-0691.2011.03570.x> PMID: 21793988

52. Leclercq R, Canton R, Brown DF, Giske CG, Heisig P, MacGowan AP, et al. EUCAST expert rules in antimicrobial susceptibility testing. *Clin Microbiol Infect*. 2013; 19(2):141–60. <https://doi.org/10.1111/j.1469-0691.2011.03703.x> PMID: 22117544
53. Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. *Front Microbiol*. 2014; 5:643. <https://doi.org/10.3389/fmicb.2014.00643> PMID: 25505462
54. Olaitan AO, Diene SM, Kempf M, Berrazeg M, Bakour S, Gupta SK, et al. Worldwide emergence of colistin resistance in *Klebsiella pneumoniae* from healthy humans and patients in Lao PDR, Thailand, Israel, Nigeria and France owing to inactivation of the PhoP/PhoQ regulator *mgrB*: an epidemiological and molecular study. *Int J Antimicrob Agents*. 2014; 44(6):500–7. <https://doi.org/10.1016/j.ijantimicag.2014.07.020> PMID: 25264127
55. Dortet L, Cuzon G, Nordmann P. Dissemination of carbapenemase-producing Enterobacteriaceae in France, 2012. *J Antimicrob Chemother*. 2014; 69(3):623–7. <https://doi.org/10.1093/jac/dkt433> PMID: 24275115
56. Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. *FEMS Microbiol Rev*. 2011; 35(5):736–55. <https://doi.org/10.1111/j.1574-6976.2011.00268.x> PMID: 21303394
57. Kristof K, Toth A, Damjanova I, Janvari L, Konkoly-Thege M, Kocsis B, et al. Identification of a *bla*_{VIM-4} gene in the internationally successful *Klebsiella pneumoniae* ST11 clone and in a *Klebsiella oxytoca* strain in Hungary. *J Antimicrob Chemother*. 2010; 65(6):1303–5. <https://doi.org/10.1093/jac/dkq133> PMID: 20410063
58. Oteo J, Perez-Vazquez M, Bautista V, Ortega A, Zamarron P, Saez D, et al. The spread of KPC-producing Enterobacteriaceae in Spain: WGS analysis of the emerging high-risk clones of *Klebsiella pneumoniae* ST11/KPC-2, ST101/KPC-2 and ST512/KPC-3. *J Antimicrob Chemother*. 2016.
59. Maatallah M, Vading M, Kabir MH, Bakhrouf A, Kalin M, Naucner P, et al. *Klebsiella variicola* is a frequent cause of bloodstream infection in the stockholm area, and associated with higher mortality compared to *K. pneumoniae*. *PLoS ONE*. 2014; 9(11):e113539. <https://doi.org/10.1371/journal.pone.0113539> PMID: 25426853
60. Chen YT, Lin JC, Fung CP, Lu PL, Chuang YC, Wu TL, et al. KPC-2-encoding plasmids from *Escherichia coli* and *Klebsiella pneumoniae* in Taiwan. *J Antimicrob Chemother*. 2014; 69(3):628–31. <https://doi.org/10.1093/jac/dkt409> PMID: 24123430
61. Toleman MA, Bugert JJ, Nizam SA. Extensively drug-resistant New Delhi metallo-β-lactamase-encoding bacteria in the environment, Dhaka, Bangladesh, 2012. *Emerg Infect Dis*. 2015; 21(6):1027–30. <https://doi.org/10.3201/eid2106.141578> PMID: 25989320
62. Pannaraj PS, Bard JD, Cerini C, Weissman SJ. Pediatric carbapenem-resistant Enterobacteriaceae in Los Angeles, California, a high-prevalence region in the United States. *Pediatr Infect Dis J*. 2015; 34(1):11–6. <https://doi.org/10.1097/INF.0000000000000471> PMID: 25093977
63. Peirano G, Ahmed-Bentley J, Fuller J, Rubin JE, Pitout JD. Travel-related carbapenemase-producing Gram-negative bacteria in Alberta, Canada: the first 3 years. *J Clin Microbiol*. 2014; 52(5):1575–81. <https://doi.org/10.1128/JCM.00162-14> PMID: 24599977
64. Mataseje LF, Abdesselam K, Vachon J, Mitchel R, Bryce E, Roscoe D, et al. Carbapenem-producing Enterobacteriaceae in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 2010–2014. *Antimicrob Agents Chemother*. 2016; 60(11):6787–94. <https://doi.org/10.1128/AAC.01359-16> PMID: 27600052
65. Poirel L, Savov E, Nazli A, Trifonova A, Todorova I, Gergova I, et al. Outbreak caused by NDM-1- and RmtB-producing *Escherichia coli* in Bulgaria. *Antimicrob Agents Chemother*. 2014; 58(4):2472–4. <https://doi.org/10.1128/AAC.02571-13> PMID: 24514099
66. Wachino J, Arakawa Y. Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram-negative bacteria: an update. *Drug Resist Updates*. 2012; 15(3):133–48.
67. Marrs EC, Day KM, Perry JD. *In vitro* activity of mecillinam against Enterobacteriaceae with NDM-1 carbapenemase. *J Antimicrob Chemother*. 2014; 69(10):2873–5. <https://doi.org/10.1093/jac/dku204> PMID: 24917584
68. Giske CG. Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomicin, mecillinam and nitrofurantoin. *Clin Microbiol Infect*. 2015; 21(10):899–905. <https://doi.org/10.1016/j.cmi.2015.05.022> PMID: 26027916
69. Tijet N, Boyd D, Patel SN, Mulvey MR, Melano RG. Evaluation of the Carba NP test for rapid detection of carbapenemase-producing Enterobacteriaceae and *Pseudomonas aeruginosa*. *Antimicrob Agents Chemotherapy*. 2013; 57(9):4578–80.

70. Osterblad M, Hakanen AJ, Jalava J. Evaluation of the Carba NP test for carbapenemase detection. *Antimicrob Agents Chemother*. 2014; 58(12):7553–6. <https://doi.org/10.1128/AAC.02761-13> PMID: [25246404](https://pubmed.ncbi.nlm.nih.gov/25246404/)
71. Oueslati S, Nordmann P, Poirel L. Heterogeneous hydrolytic features for OXA-48-like β -lactamases. *J Antimicrob Chemother*. 2015; 70(4):1059–63. <https://doi.org/10.1093/jac/dku524> PMID: [25583748](https://pubmed.ncbi.nlm.nih.gov/25583748/)
72. Literacka E, Herda M, Baraniak A, Zabicka D, Hryniewicz W, Skoczynska A, et al. Evaluation of the Carba NP test for carbapenemase detection in Enterobacteriaceae, *Pseudomonas* spp. and *Acinetobacter* spp., and its practical use in the routine work of a national reference laboratory for susceptibility testing. *Eur J Clin Microbiol Infect Dis*. 2017; 36(11):2281–87. <https://doi.org/10.1007/s10096-017-3062-0> PMID: [28744664](https://pubmed.ncbi.nlm.nih.gov/28744664/)
73. Huang TD, Poirel L, Bogaerts P, Berhin C, Nordmann P, Glupczynski Y. Temocillin and piperacillin/tazobactam resistance by disc diffusion as antimicrobial surrogate markers for the detection of carbapenemase-producing Enterobacteriaceae in geographical areas with a high prevalence of OXA-48 producers. *J Antimicrob Chemother*. 2014; 69(2):445–50. <https://doi.org/10.1093/jac/dkt367> PMID: [24055766](https://pubmed.ncbi.nlm.nih.gov/24055766/)
74. NORM/NORM-VET. NORM/NORM-VET 2015. Usage of antimicrobial agents and occurrence of antimicrobial resistance in Norway. Tromsø/Oslo: 2016.